Author

S. E. Perea

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:differential expression· 3 Approach:experimental assay· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

G. V. Perez· 5 shared Y. Perera· 5 shared A. C. Ramon· 4 shared M. Rosales· 4 shared Y. Ke· 3 shared Y. Ramos· 3 shared A. Rodriguez-Ulloa· 2 shared D. Aguilar· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

G. V. Perez

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

On Casein Kinase-2 (CK2) deregulation in NSCLC: an enzyme subunit-centered approach

G. V. Perez, L. Chen, D. Chenyi, Y. Ying, Z. Qiang, Z. Zhiwei, Y. Ke, S. E. Perea, Y. Perera

This study investigates CK2 subunit deregulation in NSCLC using multiomics data and IHC, finding that CSNK2A1 and CSNK2B upregulation correlates with poor prognosis and tumor progression.

bioRxiv · Aug 4, 2023 · PreprintCancer Biology

Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells

D. Vazquez-Blomquist, A. C. Ramon, M. Rosales, G. V. Perez, A. Rosales, D. Palenzuela, Y. Perera, S. E. Perea

This study uses microarray profiling to analyze the time-dependent gene expression changes in AML cell lines treated with CIGB-300, identifying modulated genes and pathways involved in apoptosis, cell cycle, and inflammation.

bioRxiv · Mar 6, 2023 · PreprintCancer Biology

Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection

A. C. Ramon, G. V. Perez, E. Caballero, M. Rosales, D. Aguilar, D. M. Vazquez-Blomquist, Y. Ramos, A. Rodriguez, V. Falcon, M. P. Rodriguez, Y. Ke, Y. Perera, S. E. Perea

This study shows that CIGB-325, an anti-CK2 peptide, inhibits bovine coronavirus infection by reducing viral protein accumulation and cytopathic effects.

bioRxiv · Jun 8, 2021Pharmacology & Toxicology

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

M. Rosales, G. V. Perez, A. C. Ramon, Y. Cruz, A. Rodriguez-Ulloa, V. Besada, Y. Ramos, D. Vazquez-Blomquist, E. Caballero, D. Aguilar, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Ke, Y. Perera, S. E. Perea

This study investigates the anti-proliferative and proapoptotic effects of the CK2 inhibitor CIGB-300 on AML cells and identifies its molecular targets.

bioRxiv · May 19, 2021Cancer Biology

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

M. Rosales, A. Rodriguez-Ulloa, V. Besada, A. C. Ramon, G. V. Perez, Y. Ramos, O. Guirola, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Perera, S. E. Perea

This study examines the phosphoproteomic changes in AML cell lines treated with CX-4945, identifying key biological processes and pathways affected by CK2 inhibition.

bioRxiv · Jan 4, 2021Cancer Biology